Market Cap: $376.73M
RI
Rezolute, Inc.
RZLT
NASDAQUSD
Market Cap: $376.73M
Rezolute Engages with FDA on Phase 3 Trial for Ersodetug in Treating Congenital Hyperinsulinism Rezolute marks a pivotal moment in its ongoing mission to develop novel treatments for patients sufferin…
Rezolute Engages FDA on Phase 3 Trial for Congenital Hyperinsulinism Drug In a significant development for the biotechnology firm Rezolute, the company shares crucial insights from its recent meeting…
Severe Clinical Setback for Rezolute Raises Legal Concerns Rezolute, Inc. confronts a significant challenge as recent developments relating to its leading drug candidate pose a threat to its future pr…
Rezolute Faces Scrutiny After Failed Clinical Trial for Hypoglycemia Treatment Rezolute, Inc. is currently grappling with significant fallout following the disappointing results of its Phase 3 clinica…
Rezolute Faces Scrutiny After Phase 3 Trial Failure for Hypoglycemia Treatment Rezolute, Inc. announces a significant setback in its development pipeline following the failure of its Phase 3 sunRIZE t…
Rezolute Faces Backlash Following Failed Phase 3 Trial of Hypoglycemia Drug Rezolute, Inc. recently experiences a seismic shift in its trajectory following the failure of its Phase 3 sunRIZE trial for…
Rezolute Faces Setback After Phase 3 Trial Failure for Hypoglycemia Treatment Rezolute, Inc., a biopharmaceutical company focused on developing treatments for rare diseases, encounters a critical junc…
Rezolute Faces Setback as Phase 3 Trial for Erso Fails Rezolute, Inc. is currently grappling with significant challenges following the disappointing results of its Phase 3 sunRIZE trial for ersodetug,…
Rezolute Faces Setback as Phase 3 Trial for Erso Fails to Deliver Promising Results In a significant blow to Rezolute, Inc., the company announces the failure of its Phase 3 sunRIZE trial for ersodetu…
Rezolute Faces Setback in Hypoglycemia Drug Trial Rezolute, Inc. is currently grappling with the fallout from its recently announced results of the Phase 3 sunRIZE trial for its investigational drug,…
Rezolute Faces Scrutiny Following Phase 3 Trial Failure Rezolute, Inc. experiences significant turmoil as the company announces the failure of its Phase 3 sunRIZE trial for the drug ersodetug (erso),…
Rezolute Faces Scrutiny Following Phase 3 Trial Failure of Ersodetug Rezolute, Inc. encounters significant challenges as its anticipated drug, ersodetug (erso), fails to demonstrate efficacy in a crit…
Rezolute's Phase 3 Trial Failure Raises Investor Concerns Over Drug Efficacy Rezolute, Inc. faces significant backlash following the disappointing results from its Phase 3 sunRIZE trial for the drug e…
Rezolute Faces Scrutiny After Disappointing Clinical Trial Results Rezolute, Inc. experiences a significant setback following the announcement of its Phase 3 sunRIZE trial results for the experimental…
Rezolute's Setback in Hypoglycemia Treatment Raises Investor Concerns Rezolute, Inc. faces a significant setback following the disappointing results from its Phase 3 sunRIZE trial for the hypoglycemia…
Rezolute Faces Scrutiny After Disappointing Clinical Trial Results Rezolute, Inc. (NASDAQ: RZLT) experiences a significant setback following the announcement of unsuccessful results from its Phase 3 s…
Rezolute Faces Scrutiny Following Disappointing Clinical Trial Results Rezolute, Inc. finds itself at the center of controversy following the release of unsuccessful results from its Phase 3 clinical…